ArticleActa paediatrica (Oslo, Norway : 1992)2021
Metabolic bone disease of prematurity-National survey of current neonatal and paediatric endocrine approaches.
Article in Acta paediatrica (Oslo, Norway : 1992), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Pooled it
- Modalities of Vitamin D Administration to Preterm Infants: Impact on 25 OH Vitamin D Levels.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- Interventions for metabolic bone disease of prematurity: A systematic review and meta-analysis.Metabolism open · 2026Article
- The Critical Role of Vitamin D Supplementation for Skeletal and Neurodevelopmental Outcomes in Preterm Neonates.Nutrients · 2025Review
- Vitamin D: What We Know and What We Still Do Not Know About Vitamin D in Preterm Infants-A Literature Review.Children (Basel, Switzerland) · 2025Review
- Invited Mini Review Metabolic Bone Disease of Prematurity: Overview and Practice Recommendations.Hormone research in paediatrics · 2025Review
- A Multidisciplinary and a Comprehensive Approach to Reducing Fragility Fractures in Preterm Infants.Current pediatric reviews · 2024Review
- Prenatal and Neonatal Bone Health: Updated Review on Early Identification of Newborns at High Risk for Osteopenia.Nutrients · 2023Review
- Don't Forget the Bones: Incidence and Risk Factors of Metabolic Bone Disease in a Cohort of Preterm Infants.International journal of molecular sciences · 2022Article
- Osteopenia of prematurity and associated nutritional factors: case-control study.BMC pediatrics · 2022Article
- Are we undertreating calcium deficiency in metabolic bone disease of prematurity? A case report and review.Frontiers in pediatrics · 2022Article
- Rickets in Children: An Update.Biomedicines · 2021Review
- Metabolic bone disease of prematurity-National survey of current neonatal and paediatric endocrine approaches.Acta paediatrica (Oslo, Norway : 1992) · 2021Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to identify current trends in the management of metabolic bone disease of prematurity (MBDP) in the United Kingdom.
methodsA nationwide electronic survey was disseminated to all neonatal networks across the United Kingdom, as well as to paediatric endocrinologists for comparison. Weighted averages were used to compare relative importance placed on screening and diagnostic investigations (1 = not important, 5 = essential).
resultsSixty-nine individuals responded from 53 neonatal units. Greatest emphasis was placed on levels of serum phosphate and alkaline phosphatase for screening (weighted average 4.5 and 4.6, respectively), diagnosis (weighted average 4.1 and 4.5, respectively) and monitoring (93% and 97% of neonatal responders, respectively) of MBDP by neonatologists. Although similar results were obtained for endocrinologists, significantly greater emphasis was placed on plasma parathyroid hormone (PTH) level for screening, diagnosis and monitoring (p < 0.001 for each). Phosphate supplementation was reported almost universally by neonatal responders (99%), but was significantly less for endocrine responders (62%) for the treatment of MBDP (p < 0.001).
conclusionThere is an under-utilisation of plasma PTH as a screening, diagnostic and monitoring investigation to guide appropriate supplementation for MBDP by neonatologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.